STEPHEN COOLEY: Open Payments
NPI 1306304704 · FRESNO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,182 in 213 payments from 19 companies in 2025. Trend: 2023 $3,245 · 2024 $3,494 · 2025 $3,182
Food & beverage: $3,182
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 50 | $646 |
| Incyte Corporation | 30 | $376 |
| Arcutis Biotherapeutics, Inc. | 30 | $371 |
| UCB, Inc. | 7 | $198 |
| GENZYME CORPORATION | 6 | $189 |
| Janssen Biotech, Inc. | 22 | $188 |
| LEO Pharma Inc. | 12 | $182 |
| Novartis Pharmaceuticals Corporation | 6 | $160 |
| Galderma Laboratories, L.P. | 12 | $154 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 8 | $144 |
Products named: OPZELURA, Zoryve, SKYRIZI, DUPIXENT, RINVOQ, Bimzelx, TREMFYA, NEMLUVIO.
Industry payments across CA — which companies pay providers there.
